Company: VERA
Filing Date: 2025-05-19
Form Type: 8-K
Source: 0000950170-25-074446
Chunk: 0

Company: Vera Therapeutics, Inc.
Filing Date: 2025-05-19
Form: 8-K
Item: Item 5.07
Chunk 0
---
Item 5.07 Submission of Matters to a Vote of Security Holders.

On May 14, 2025, Vera Therapeutics, Inc. (the “ Company”) held its 2025 Annual Meeting of Stockholders (the “ Annual Meeting”). As of March 17, 2025, the record date for the Annual Meeting, 63,771,720 shares of Class A common stock were outstanding and entitled to vote at the Annual Meeting. A summary of the matters voted upon by stockholders at the Annual Meeting is set forth below. Each matter is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 3, 2025 (the “ Proxy Statement”).

Proposal 1 - Election of Directors.

The Company’s stockholders elected the three persons listed below as Class I Directors, each to serve until the Company’s 2028 Annual Meeting of Stockholders and until their respective successors are duly elected and qualified, or, if sooner, such director’s death, resignation or removal. The final voting results are as follows:

                                Votes For      Votes Withheld      Broker Non-Votes  
 ─────────────────────────────────────────────────────────────────────────────────────
  Marshall Fordyce, M. D.      49,472,959           5,393,304             1,795,714  
  Beth Seidenberg, M. D.       49,033,555           5,832,708             1,795,714  
  Kimball Hall                 49,366,281           5,499,982             1,795,714  

Proposal 2 - Ratification of the Appointment of Independent Registered Public Accounting Firm.

The Company’s stockholders ratified the selection by the Audit Committee of the Company’s Board of Directors of KPMG LLP as the independent registered public accounting firm of the Company for its fiscal year ending December 31, 2025. The final voting results are as follows:

         For      Against      Abstain  
 ────────────────────────────────────────
  56,649,390        3,556        9,031  

Proposal 3 - Advisory Vote on Executive Compensation.

The Company’s stockholders approved, on an advisory basis, the compensation awarded to the Company’s named executive officers, as disclosed in the Proxy Statement. The final voting results are as follows:

         For        Against      Abstain      Broker Non-Votes  
 ─────────────────────────